Company intelligence / Profile preview
Treos Bio
London, England, United Kingdomtreosbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead product PolyPEPI1018 for colorectal cancer has demonstrated robust immunological responses in clinical trials, turning "cold" tumors to "hot" with associated clinical benefits. Effects observed in first-line maintenance MSS mCRC (OBERTO-101) and late-stage MSS mCRC in combination with chemotherapy (OBERTO-201) and PD-L1 inhibitor (OBERTO-301).
- Therapeutic areas
- Oncology
- Modalities
- Peptide vaccinesTherapeutic vaccinesSynthetic peptide vaccines
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Collaboration with Roche for PD-L1 inhibitor combination therapy
Beyond the preview
Go deeper on Treos Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Treos Bio.